Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101.
Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics
Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.